The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Open accessAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,628
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., Ng, O.-T., Marimuthu, K., Ang, L. W., Mak, T. M., et al. (2020) · JAMA · doi:10.1001/jama.2020.3204 · Cited by 2,059
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
Booth, C. M. (2003) · JAMA · doi:10.1001/jama.289.21.joc30885 · Cited by 1,406
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Arabi, Y. M., Mandourah, Y., Al-Hameed, F., Sindi, A. A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R., Al-Omari, A., Kharaba, A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1172oc · Cited by 1,122
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105932 · Cited by 937 · cited 1×
“0 μM were demonstrated, respectively [15].”
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.013056 · Cited by 850
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117477 · Cited by 715
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01594 · Cited by 643
Lee, N., Allen Chan, K. C., Hui, D. S., Ng, E. K. O., Wu, A., Chiu, R. W. K., Wong, V. W. S., Chan, P. K. S., Wong, K. T., Wong, E., et al. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.07.006 · Cited by 636
Lim, J., Jeon, S., Shin, H.-Y., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K.-W., Kang, Y. M., Lee, B., & Park, S.-J. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e79 · Cited by 636
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604
Wang, Z., Chen, X., Lu, Y., Chen, F., & Zhang, W. (2020) · BioScience Trends · doi:10.5582/bst.2020.01030 · Cited by 544
Touret, F., & de Lamballerie, X. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104762 · Cited by 541
A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Baliji, S., Chaudhuri, R., Fu, W., Prabhakar, B. S., Johnson, M. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805240105 · Cited by 507
Chan, K., Lai, S. T., Chu, C., Tsui, E. L. H., Tam, C. Y., Wong, M. M.-L., Tse, M. W., Que, T. L., Peiris, M. J. S., Sung, J. J. �., et al. (2003) · PubMed · Cited by 423
Late Ebola virus relapse causing meningoencephalitis: a case report
Jacobs, M., Rodger, A., Bell, D. J., Bhagani, S., Cropley, I., Filipe, A., Gifford, R. J., Hopkins, S., Hughes, J., Jabeen, F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30386-5 · Cited by 361
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
Xu, J., Shi, P.-Y., Li, H., & Zhou, J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00052 · Cited by 340
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
Kotch, C., Barrett, D., & Teachey, D. T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1629904 · Cited by 324
Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities
Biot, C., Daher, W., Chavain, N., Fandeur, T., Khalife, J., Dive, D., & De Clercq, E. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0601856 · Cited by 320
O'Keefe, B. R., Giomarelli, B., Barnard, D. L., Shenoy, S. R., Chan, P. K. S., McMahon, J. B., Palmer, K. E., Barnett, B. W., Meyerholz, D. K., Wohlford-Lenane, C. L., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02322-09 · Cited by 303
Xu, Z., Shi, D., Han, J.-B., Ling, Y., Jiang, X., Lu, X., Li, C., Gong, L., Ge, G., Zhang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01429-0 · Cited by 301
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Rossignol, J.-F. (2016) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.04.001 · Cited by 290
Park, J. H., Romero, F. A., Taur, Y., Sadelain, M., Brentjens, R. J., Hohl, T. M., & Seo, S. K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy152 · Cited by 276
Treatment of Severe Acute Respiratory Syndrome With Glucosteroids
Chen, R.-C., Tang, X.-P., Tan, S.-Y., Liang, B.-L., Wan, Z.-Y., Fang, J.-Q., & Zhong, N. (2006) · Chest · doi:10.1378/chest.129.6.1441 · Cited by 274
Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., & Rossignol, J.-F. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70717-0 · Cited by 251
Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
Lin, M.-H., Moses, D. C., Hsieh, C.-H., Cheng, S.-C., Chen, Y.-H., Sun, C.-Y., & Chou, C.-Y. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.015 · Cited by 250
Arabi, Y. M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz544 · Cited by 248
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
Tan, E. L. C., Ooi, E. E., Lin, C.-Y., Tan, H. C., Ling, A. E., Lim, B., & Stanton, L. W. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1004.030458 · Cited by 237
Auyeung, T. W., Lee, J. S. W., Lai, W. K., Choi, C. H., Lee, H. K., Lee, J. S., Li, P. C., Lok, K. H., Ng, Y. Y., Wong, W. M., et al. (2005) · Journal of Infection · doi:10.1016/j.jinf.2004.09.008 · Cited by 208
Song, Y., Yao, C., Yao, Y., Han, H., Zhao, X., Yu, K., Liu, L., Xu, Y., Liu, Z., Zhou, Q., et al. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003842 · Cited by 159
The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019
Han, W., Quan, B., Guo, Y., Zhang, J., Lu, Y., Feng, G. L., Wu, Q., Fang, F., Cheng, L., Jiao, N., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25711 · Cited by 148
First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease
Dörnemann, J., Burzio, C., Ronsse, A., Sprecher, A., Clerck, H. D., Herp, M. V., Kolié, M.-C., Yosifiva, V., Caluwaerts, S., McElroy, A. K., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw493 · Cited by 138
and the Saudi Critical Care Trials group, Arabi, Y. M., Asiri, A. Y., Assiri, A. M., Jokhdar, H., Alothman, A. F., Balkhy, H. H., AlJohani, S. M., Harbi, S. A. A., Kojan, S. M., et al. (2020) · Trials · doi:10.1186/s13063-019-3846-x · Cited by 128
First 12 patients with coronavirus disease 2019 (COVID-19) in the United StatesPreprint
The COVID-19 Investigation Team, Kujawski, S. A., Wong, K. K., Collins, J. P., Epstein, L. H., Killerby, M. E., Midgley, C. M., Abedi, G. R., Ahmed, N. S., Almendares, O. M., et al. (2020) · medRxiv · doi:10.1101/2020.03.09.20032896 · Cited by 118
Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck
Stevens, M., Patel, P., & Nori, P. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.69 · Cited by 108
Clinical Pharmacokinetics of Slow-Acting Antirheumatic Drugs
Tett, S. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325050-00005 · Cited by 95
Gamiño-Arroyo, A. E., Guerrero, M. L., McCarthy, S., Ramírez‐Venegas, A., Llamosas‐Gallardo, B., Galindo‐Fraga, A., Moreno‐Espinosa, S., Roldán-Aragón, Y. A., Araujo-Meléndez, J., Hunsberger, S., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz100 · Cited by 63
Cited by
Koehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951
COVID-19 and the human innate immune system
Schultze, J. L., & Aschenbrenner, A. C. (2021) · Cell · doi:10.1016/j.cell.2021.02.029 · Cited by 714
“Targeting several of these pathways simultaneously (e.g., by inhibiting Janus kinases)might overcome such limitations (McCreary and Pogue, 2020; Wu and Yang, 2020).”
A review: Mechanism of action of antiviral drugs
Kausar, S., Said Khan, F., Ishaq Mujeeb Ur Rehman, M., Akram, M., Riaz, M., Rasool, G., Hamid Khan, A., Saleem, I., Shamim, S., & Malik, A. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211002621 · Cited by 429
COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
Arastehfar, A., Carvalho, A., van de Veerdonk, F. L., Jenks, J. D., Koehler, P., Krause, R., Cornely, O. A., S. Perlin, D., Lass-Flörl, C., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6020091 · Cited by 421
Antiviral treatment of COVID-19
ŞİMŞEK YAVUZ, S., & ÜNAL, S. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-145 · Cited by 367
Metadata
- Authors
- McCreary, E. K., & Pogue, J. M.
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-23
- Volume
- 7
- Issue
- 4
- Pages
- ofaa105-ofaa105
- ISSN
- 2328-8957 (ISSN-L)
- OpenAlex
- W3013369257
- Cited by
- 334
- References
- 63
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.